Forekomsten af brystsymptomer og uterin blødning var hos raloxifenbehandlede kvinder signifikant lavere end hos kvinder, som blev behandlet med den ene eller anden form for hormonal substitutionsbehandling.
The incidence of breast symptoms and uterine bleeding in raloxifene treated women was significantly lower than in women treated with either form of HRT.